• Atos to begin a due diligence phase with Airbus on the basis of an indicative enterprise value offer of 1.5 to 1.8 billion euros for BDS.
  • Airbus aircraft deliveries slightly exceeded target of 720 in 2023, according to several sources.
  • Tesla achieves its delivery target but falls behind BYD in Q4.
  • HSBC will launch Zing app to rival Wise and Revolut.
  • KKR acquires Global Atlantic Financial Group.
  • The Travelers Companies completes the acquisition of cyber-insurance specialist Corvus Insurance.
  • SoftwareOne acquires Novis Euforia, a provider of SAP and cloud services.
  • Hyundai sets a global sales target of 4.24 million vehicles in 2024.
  • Chevron expects up to $4 billion in accounting charges in Q4, due to regulatory concerns in California.
  • AstraZeneca signs exclusive worldwide licensing agreement with Allorion Therapeutics for potential lung cancer treatment.
  • Novartis signs collaboration with Voyager Therapeutics on the rights to a gene therapy for the treatment of Huntington's disease and spinal muscular atrophy.
  • Pfizer gains 1.2% in pre-market trading and Moderna advanced 2.9% after having already gained 13.1% the previous day, following the upgrade of Oppenheimer's recommendation to "outperform" on the stock and the laboratory's confirmation of its sales growth target for 2025.
  • Alphabet and Meta Platforms are likely to have paid the fines imposed by Russian courts, suggests the Russian state bailiffs' debtor database consulted by Reuters on Wednesday.
  • BrightSpring Health Services, a healthcare services platform backed by KKR, filed for an initial public offering in New York on Tuesday evening, reviving its IPO project more than a year after it was put on hold due to economic uncertainties.
  • Walt Disney announced on Wednesday that investment firm ValueAct Capital will advise on its strategy in the battle with activist investor Nelson Peltz at the 2024 annual meeting.